Shares in Diamyd AB plunged 85 percent Monday on news that its immunotherapy treatment for Type I diabetes, also called Diamyd, missed the primary endpoint of a European Phase III trial.
Shares in Wilex AG rose almost 20 percent earlier this week on news that the company secured $19 million up front and could bank another $20 million within 12 months as part of a U.S. deal with Prometheus Laboratories Inc. for its Phase III anticancer antibody Rencarex (girentuximab), which is potentially worth more than $145 million.
In keeping with its reputation for doing things quickly, Molecular Partners AG has secured a potential $420 million deal – a sizable $45 million of which is up front – with Allergan Inc. for its lead molecule, MP0112, within days of reporting positive Phase I/IIa data.
Shares in Wilex AG rose almost 20 percent Monday on news that the company secured $19 million up front and could bank another $20 million within 12 months as part of a U.S. deal with Prometheus Laboratories Inc. for its Phase III anticancer antibody Rencarex (girentuximab), which is potentially worth more than $145 million. (BioWorld International)
Kuros Biosurgery AG's longstanding relationship with Baxter International Inc. has dwindled to just one development program following a decision by the latter to hand back rights to three programs it had previously licensed: KUR-111, KUR-113 and KUR-115.
